Trial · NCT02580240
Initiation of Hydrocortisone for the Treatment of Septic Shock
NCT02580240, Not applicable, Completed, Northern Jiangsu People's Hospital; results first posted 2017-08-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Initiation of Hydrocortisone for the Treatment of Septic Shock. Trials, record NCT02580240. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02580240
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Initiation of Hydrocortisone for the Treatment of Septic Shock
- NCT number
- NCT02580240
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 118 participants, actual
- Lead sponsor
- Northern Jiangsu People's Hospital
- Conditions
- Septic Shock
- Interventions
- Hydrocortisone, saline
- First posted
- 2015-10-20
- Last updated
- 2017-08-07
- Results first posted
- 2017-08-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 28-day Mortality | 28 days | Death from any cause at 28 days after the onset of septic shock |
| Secondary | All Cause Mortality | 90 days | Death from any cause at 90 days after the onset of septic shock |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 28-day Mortality | 28 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | All Cause Mortality | 90 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 28-day Mortality | Placebo | 19 | Participants | ||
| 28-day Mortality | Hydrocortisone | 23 | Participants | ||
| All Cause Mortality | Placebo | 19 | Participants | ||
| All Cause Mortality | Hydrocortisone | 23 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 62 | |
| Overall Study | STARTED | Hydrocortisone | 58 | |
| Overall Study | COMPLETED | Placebo | 60 | |
| Overall Study | COMPLETED | Hydrocortisone | 58 | |
| Overall Study | NOT COMPLETED | Placebo | 2 | |
| Overall Study | NOT COMPLETED | Hydrocortisone | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | muscle weakness | Musculoskeletal and connective tissue disorders | Placebo | 2 | 60 | |
| other | muscle weakness | Musculoskeletal and connective tissue disorders | Hydrocortisone | 1 | 58 | |
| serious | hyperglycemia | Endocrine disorders | Placebo | 0 | 60 | |
| serious | hyperglycemia | Endocrine disorders | Hydrocortisone | 1 | 58 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 19 | 60 |
| Total, all-cause mortality | Hydrocortisone | 23 | 58 |
| Total, other adverse events | Placebo | 2 | 60 |
| Total, other adverse events | Hydrocortisone | 1 | 58 |
| Total, serious adverse events | Placebo | 0 | 60 |
| Total, serious adverse events | Hydrocortisone | 1 | 58 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28615145 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Hydrocortisone vs Placebo: 28-day Mortality | Trial comparisons |
| Hydrocortisone vs Placebo: All Cause Mortality | Trial comparisons |
| Hydrocortisone vs Placebo: deaths from any cause | Trial comparisons |
| Hydrocortisone vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02580240
GET https://conductscience.org/api/trials/v1/NCT02580240/registered